Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study
Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled in ...
AZoM on MSN8h
Stable and Efficient Electron Transport Layer for CO2 Conversion
NC State researchers reveal a tincone thin film with improved stability and electrochemical properties, paving the way for ...
AHA/ASA Journals14h
XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity
BACKGROUND: Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these prevalent outcomes ...
C&EN5d
Chemoproteomic Profiling of C. albicans for Characterization of Antifungal Kinase Inhibitors
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States Department of Pharmacology, University of ...
Yahoo Finance4d
Co-Diagnostics, Inc. (CODX)
After hours: March 21 at 5:42:49 PM EDT Loading Chart for CODX ...
Bloomberg L.P.4d
Coca-Cola Co/The
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...